Price (delayed)
$31.22
Market cap
$3.11B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3
Enterprise value
$2.46B
Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To
There are no recent dividends present for ZLAB.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.